Highlights Cybin Inc.

Equities

HELP

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-06 pm EST			5-day change	1st Jan Change
5.980 ^USD	+2.05%		-9.67%	-26.89%

Feb. 02	Jefferies Initiates Coverage on Cybin With Buy Rating, CA$29.88 Price Target	MT
Jan. 05	Cybin Inc.(NasdaqGM:HELP) added to NASDAQ Composite Index	CI

Highlights

Jan. 05	Helus Pharma begins Nasdaq trading, advances mental health therapies	RE
Dec. 18	Alerts, brief on Cybin transferring US listing to Nasdaq withdrawn	RE
Nov. 13	Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
Nov. 04	Compass Pathways to expedite launch of its experimental depression therapy	RE
25-09-23	Cybin Inc. Highlights Upcoming Clinical Milestones	CI
25-09-17	Cybin cuts size of mixed shelf offering - SEC filing	RE
25-09-08	Cybin Inc. Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder	CI
25-08-26	Cybin Inc. Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder	CI
25-08-25	AbbVie targets psychedelic-based depression drug market with $1.2 billion deal	RE
25-08-13	Cybin Inc. Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
25-08-07	Cybin Says Received Approval to Initiate Trial for Major Depressive Disorder in 3 Countries	MT
25-08-07	Cybin Inc. Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder	CI
25-08-07	Cybin receives European approval for Embrace, a multinational phase 3 study evaluating CYB003	RE
25-07-17	Cybin Inc. Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder	CI
25-07-17	Cybin receives UK MHRA approval to commence EMBRACE, a multinational pivotal study evaluating CYB003 for the adjunctive treatment of Major Depressive Disorder	RE
25-07-01	Cybin Inc. Reports Earnings Results for the Full Year Ended March 31, 2025	CI
25-06-13	Cybin Inc. Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics	CI
25-06-03	Cybin Granted Additional US Patent for Potential Anxiety Disorder Treatments	MT
25-05-15	Cybin Says Thermo Fisher Scientific to Offer US-Based Manufacturing for Its Depressive Disorder Program	MT
25-05-08	Cybin Inc. Announces Additional U.S. Patent Supporting Its Cyb003 Therapy Program in Phase 3 Development for Major Depressive Disorder	CI
25-04-23	Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003	CI
25-04-21	Cybin Inc. Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs	CI
25-02-10	Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	CI
25-01-15	Cybin, Segal Trials Collaborate to Advance Major Depressive Disorder Treatment	MT
25-01-15	Cybin Launches Strategic Clinical Site Partnerships to Support Paradigm, A Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Cybin Inc.

Equities

HELP

CA23256X4075

Biotechnology & Medical Research

Highlights

Filters